This collection of case-based expert commentaries reinforces core concepts relevant to the contemporary management of HIV. Various experts provide practical perspectives on recent treatment advances and everyday clinical challenges.
Here is my take on how emerging investigational agents may address unmet needs in HIV treatment.
Here is my take on current data with dual-therapy regimens and when they might be considered.
Will long-acting cabotegravir plus rilpivirine injections satisfy patient desire for less frequent dosing? Here is my take.
In an older patient managing hypertension, reactive airways disease, and moderate renal insufficiency, what ART regimen would you recommend?
Which statins should be avoided in patients receiving boosted ART regimens?
What qualifies an HIV-infected past or current smoker for annual lung cancer screening using low-dose CT scans?
In some cases, gaining trust may be the most important aspect of a patient’s care.
Understanding a patient’s life circumstances may be as important as any other aspect of providing good care.
One-tablet regimens may not always be the best choice of ART, but the best choice is always the one the patient is willing to take.
What key factors influence the choice of ART in older women?
Which ARV classes best avoid DDIs with hormonal contraception?
Which regimen may work best during the third trimester?
For a newly diagnosed patient with an OI and pending resistance test results, when and with what would you recommend initiating ART?
Would you switch a virologically suppressed patient who is experiencing PI toxicity to a PI-sparing regimen if they had a history of nonadherence and resistance?
What is the optimal ART regimen for a patient with CKD and CVD who desires an STR?
Is switching TDF to TAF justified in osteopenic women?
Is the switch to a 2-drug regimen in virologically suppressed HIV-infected patients feasible?
How do phase III data on doravirine affect the potential for future therapy with NNRTIs?
How do phase III data on bictegravir and doravirine affect the potential future HIV treatment landscape? Here’s my take.
Can switching ART improve cardiovascular or bone health?
Should dual-therapy ART be considered in the first-line setting for some patients?
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.